Stock Scorecard

Stock Summary for Regeneron Pharmaceuticals Inc (REGN) - $547.36 as of 7/4/2025 2:02:10 AM EST

Total Score

20 out of 30

Safety Score

62 out of 100

Currently on the following lists
Dividend Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for REGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for REGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for REGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for REGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for REGN (62 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for REGN

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 7/3/2025 1:37:00 PM
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug 7/3/2025 1:16:00 PM
Lynozyfic™ ( linvoseltamab-gcpt ) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma 7/2/2025 3:00:00 PM
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 7/1/2025 8:01:00 PM
Regeneron Pharmaceuticals Unusual Options Activity For July 01 - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 7/1/2025 7:04:00 PM
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 6/26/2025 8:05:00 PM
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 6/26/2025 8:05:00 PM
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? - Nektar Therapeutics ( NASDAQ:NKTR ) 6/25/2025 5:42:00 PM
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? 6/25/2025 2:03:00 PM
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization 6/24/2025 11:30:00 AM

Financial Details for REGN

Company Overview
Ticker REGN
Company Name Regeneron Pharmaceuticals Inc
Country USA
Description Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 7/30/2025

Stock Price History
Last Day Price 547.36
Price 4 Years Ago 629.82
Last Day Price Updated 7/4/2025 2:02:10 AM EST
Last Day Volume 456,413
Average Daily Volume 1,394,173
52-Week High 1,207.86
52-Week Low 476.49
Last Price to 52 Week Low 14.87%

Valuation Measures
Trailing PE 13.93
Industry PE 21.93
Sector PE 40.90
5-Year Average PE 25.05
Free Cash Flow Ratio 18.80
Industry Free Cash Flow Ratio 17.71
Sector Free Cash Flow Ratio 32.91
Current Ratio Most Recent Quarter 4.93
Total Cash Per Share 29.11
Book Value Per Share Most Recent Quarter 277.50
Price to Book Ratio 2.01
Industry Price to Book Ratio 34.53
Sector Price to Book Ratio 30.76
Price to Sales Ratio Twelve Trailing Months 4.20
Industry Price to Sales Ratio Twelve Trailing Months 121.97
Sector Price to Sales Ratio Twelve Trailing Months 35.60
Analyst Buy Ratings 13
Analyst Strong Buy Ratings 6

Share Statistics
Total Shares Outstanding 106,148,000
Market Capitalization 58,101,169,280
Institutional Ownership 91.99%

Dividends
Ex-Dividend Date 5/20/2025
Previous Dividend Amount 0.8800
Current Dividend Amount 0.8800
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 1.76
Trailing Annual Dividend Yield 0.32%
Forward Annual Dividend Rate 3.52
Forward Annual Dividend Yield 0.64%
5-Year Dividend Payments Count 2
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio 4.48%

Income Statement
Quarterly Earnings Growth YOY 15.90%
Annual Earnings Growth 11.61%
Reported EPS 12 Trailing Months 39.33
Reported EPS Past Year 8.22
Reported EPS Prior Year 45.64
Net Income Twelve Trailing Months 4,499,300,000
Net Income Past Year 4,412,600,000
Net Income Prior Year 3,953,600,000
Quarterly Revenue Growth YOY -3.70%
5-Year Revenue Growth 12.55%
Operating Margin Twelve Trailing Months 19.90%

Balance Sheet
Total Cash Most Recent Quarter 3,090,200,000
Total Cash Past Year 2,488,200,000
Total Cash Prior Year 2,730,000,000
Net Cash Position Most Recent Quarter 1,105,400,000
Net Cash Position Past Year 503,800,000
Long Term Debt Past Year 1,984,400,000
Long Term Debt Prior Year 1,982,900,000
Total Debt Most Recent Quarter 1,984,800,000
Equity to Debt Ratio Past Year 0.94
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 29,353,600,000
Total Stockholder Equity Prior Year 25,973,100,000
Total Stockholder Equity Most Recent Quarter 29,387,600,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 3,020,100,000
Free Cash Flow Per Share Twelve Trailing Months 28.45
Free Cash Flow Past Year 3,664,600,000
Free Cash Flow Prior Year 3,667,600,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -11.91
MACD Signal -15.05
20-Day Bollinger Lower Band 454.90
20-Day Bollinger Middle Band 594.12
20-Day Bollinger Upper Band 733.35
Beta 0.31
RSI 45.58
50-Day SMA 795.03
150-Day SMA 807.92
200-Day SMA 763.09

System
Modified 7/3/2025 9:08:11 AM EST